Compare Allstate Corp (ALL) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs Cassava Sciences Inc — how do they compare? Allstate Corp trades at $257.78 (market cap $66.31B), while Cassava Sciences Inc trades at $0.95 (market cap $47.75M). The key difference: Allstate Corp is far larger — about 1388.7× Cassava Sciences Inc's market cap, and Allstate Corp pays a 1.65% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| ALL | FLNA | |
|---|---|---|
Market Cap | $66.31B | $47.75M |
Sector | Financials | Health |
52-Week High | $275.11 | $4.64 |
52-Week Low | $190.00 | $0.87 |
Enterprise Value | $74.96B | -$34.93M |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $269.67, up 1.0% today, near its 52-week high. The stock shows bullish technical signals with strong support at $267. Fundamentally, the company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. The P/E ratio of 5.25 indicates attractive valuation relative to earnings. Recent news highlights strong operational performance but questions sustainability.
Outlook is positive with earnings beats and dividend payments, but risks include potential normalization of underwriting margins and competitive pressures. Analyst consensus is mixed with a $266.47 price target, suggesting limited upside from current levels. Investment appeal lies in valuation and profitability, though sustainability concerns warrant caution.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
